Nesiritide Peptide: Recombinant BNP, ASCEND-HF and Why It Was Discontinued
Nesiritide peptide guide covering recombinant human BNP biology, the Natrecor heart-failure label, VMAC and ASCEND-HF evidence, safety limits and discontinuation.
Nesiritide is a peptide drug with an unusually instructive history. It is a recombinant version of human B-type natriuretic peptide, or BNP, a 32 amino acid hormone the heart's ventricles release in response to wall stress. Sold as Natrecor, it was approved, heavily promoted, scrutinized for safety, tested in one of the largest acute heart-failure trials ever run, found to be neutral, and ultimately discontinued.
That arc matters. Nesiritide is not a research-market "wellness" peptide and it is not a current therapy you can be prescribed. It is a case study in how a biologically plausible mechanism and early hemodynamic data can still fail to translate into outcome benefit. Understanding it helps you read peptide claims more critically.
This guide is educational and not medical advice. Nesiritide was a prescription-only intravenous hospital drug, and it is no longer marketed. Nothing here is a protocol, a dose recommendation, or a suggestion that it can or should be used. For background on what peptides are and how researchers think about them, see what peptides are.
Nesiritide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | Recombinant human B-type natriuretic peptide (hBNP), a 32 amino acid peptide produced in E. coli. |
| Brand name | Natrecor, developed by Scios (later part of Johnson & Johnson). |
| Approval | FDA-approved in August 2001 for acutely decompensated heart failure with dyspnea at rest or with minimal activity. |
| Route | Intravenous only, given as a hospital bolus plus continuous infusion. |
| Main effect | Vasodilation and reduced cardiac filling pressures via natriuretic-peptide receptor signaling and cGMP. |
| Pivotal outcome trial | ASCEND-HF (7,141 patients) found no benefit on death or rehospitalization. |
| Current status | Discontinued and no longer marketed. |
How Recombinant BNP Was Supposed To Work
Native BNP is a counter-regulatory hormone. When the heart is overloaded and stretched, ventricular myocytes secrete BNP, which then acts to offload the circulation. Nesiritide reproduces that signal in pharmacologic amounts.
According to the Natrecor prescribing information, human BNP binds the particulate (membrane-bound) guanylate cyclase receptor of vascular smooth muscle and endothelial cells. This receptor is the natriuretic peptide receptor-A, or NPR-A. Binding raises intracellular cyclic guanosine monophosphate, or cGMP, which relaxes vascular smooth muscle.
The downstream effects are what made nesiritide attractive in acute heart failure: dilation of both veins and arteries, lower pulmonary capillary wedge pressure, reduced cardiac filling pressures, and counter-regulation of the renin-angiotensin-aldosterone system. In principle, that should relieve congestion and breathlessness without the direct heart-rate and arrhythmia costs of older inotropes.
This cGMP-driven, receptor-mediated logic is shared by other therapeutic peptides that work through guanylate cyclase pathways. The gut peptide linaclotide, for example, activates a related guanylate cyclase-C receptor in the intestine to raise cGMP locally. Same second messenger, completely different tissue, completely different use. Mechanism alone never tells you the clinical value.
Approval, Origin And The Label
Nesiritide was developed by Scios, a biotechnology company later acquired by Johnson & Johnson. The FDA approved it in August 2001. The approved indication, per the label, is the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity.
The Natrecor label describes a reference regimen for the hospital setting: an intravenous bolus of 2 mcg/kg followed by a continuous infusion of 0.01 mcg/kg/min. These figures are label parameters for a discontinued hospital drug, not a recommendation, and they were always meant to be administered and titrated under monitoring by clinicians. The label's pharmacology section notes a terminal elimination half-life of roughly 18 minutes, although the hemodynamic effects can persist for several hours.
That short half-life is a recurring theme in injectable peptides: rapid clearance often means continuous infusion rather than a single shot. For more on why that matters, see the peptide half-life guide.
What The Evidence Actually Showed
The evidence for nesiritide is a study in the gap between hemodynamics and outcomes.
The pivotal hemodynamic trial, VMAC (Vasodilation in the Management of Acute Congestive Heart Failure), was published in JAMA in 2002. It randomized patients hospitalized with decompensated heart failure to nesiritide, intravenous nitroglycerin, or placebo added to standard care. Nesiritide lowered pulmonary capillary wedge pressure more than nitroglycerin or placebo over the first hours and modestly improved self-reported dyspnea. That hemodynamic signal supported approval.
But hemodynamic improvement is a surrogate, not a hard outcome. In 2005, pooled analyses by Sackner-Bernstein and colleagues raised two safety alarms. One JAMA analysis suggested a possible increase in short-term mortality. A Circulation analysis suggested an increased risk of worsening renal function at approved doses. These were pooled estimates from relatively small trials with few events, the confidence intervals were wide, and the findings were contested, but they triggered intense scrutiny, label warnings, and a sharp drop in clinical enthusiasm.
To settle the question, the manufacturer ran ASCEND-HF, published in the New England Journal of Medicine in 2011. With 7,141 patients, it was far larger than anything before it. The co-primary endpoints were change in dyspnea at 6 and 24 hours and the composite of death or heart-failure rehospitalization at 30 days. The results were essentially neutral. Nesiritide produced only a small improvement in dyspnea that did not meet the prespecified significance threshold, and it had no effect on death or rehospitalization at 30 days. It did not worsen renal function, which reassured against the earlier signal, but it did cause significantly more hypotension. The authors concluded plainly that nesiritide could not be recommended for the broad population of patients with acute decompensated heart failure.
That is the honest summary: a clear mechanism, a real hemodynamic effect, a genuine safety debate, and ultimately no demonstrated outcome benefit in a definitive trial.
Safety Limits
Even as a hospital drug, nesiritide carried meaningful risks. The dominant one is hypotension, a direct extension of its vasodilatory mechanism.
| Safety issue | Why it matters |
|---|---|
| Hypotension | The main dose-limiting effect; ASCEND-HF showed significantly more hypotension, including symptomatic hypotension, versus placebo. |
| Renal function concern | FDA-dose pooled analyses suggested worsening renal function; ASCEND-HF did not confirm net harm but the debate shaped its decline. |
| Mortality debate | A 2005 pooled analysis raised a short-term death signal; later large-trial data did not confirm an increase. |
| Narrow setting | Indicated only for acute, in-hospital, intravenous use with monitoring; never a chronic or outpatient therapy. |
| No remaining access | The product was discontinued, so there is no current approved supply or labeled use. |
The hypotension risk is the practical core of its safety story. Because the effect can outlast the short plasma half-life, blood pressure could stay low after the infusion was reduced or stopped, which complicated titration.
How To Read A "BNP Peptide" Claim
Because nesiritide is a real, named, recombinant peptide, it sometimes appears in peptide-marketing language as a "natriuretic" or "heart" peptide. Apply a few filters.
First, separate mechanism from outcome. Nesiritide genuinely raises cGMP and dilates vessels. It still failed to improve survival or rehospitalization in ASCEND-HF. A plausible pathway is not proof of benefit.
Second, note the route and setting. This was an intravenous, monitored, hospital drug for an acute emergency, not something self-administered. Many clinical peptides are similarly setting-specific, including octreotide for certain hormonal and gastrointestinal conditions, teduglutide for short bowel syndrome, and icatibant for hereditary angioedema attacks. The body system and context are the whole story.
Third, check the current status. Any claim that implies you can obtain or use nesiritide today is ignoring that it was discontinued. A drug being "FDA-approved" at some point does not mean it is available or recommended now.
Fourth, watch for surrogate-endpoint hype. Improved wedge pressure or a short-term symptom score is not the same as living longer or staying out of the hospital. The nesiritide story is the textbook example of that distinction.
Bottom Line
Nesiritide is recombinant human BNP, a real peptide hormone reproduced as a drug. It works through a coherent mechanism, binding natriuretic peptide receptors, raising cGMP, and dilating blood vessels to reduce cardiac filling pressures. It earned FDA approval in 2001 for acute decompensated heart failure on the strength of hemodynamic and symptom data from trials like VMAC.
But the definitive ASCEND-HF trial found no benefit on death or rehospitalization, only a small non-significant dyspnea effect, and more hypotension. Combined with earlier safety controversies and the lack of an outcome advantage over much cheaper standard care, clinical use collapsed and the product was discontinued. There is no current approved use, no available supply, and no established protocol.
The lasting value of nesiritide is as a lesson: a beautiful mechanism and early surrogate data are not enough. Hard outcomes decide, and here they said no.
References
U.S. Food and Drug Administration. Natrecor (nesiritide) for Injection, original prescribing information (2001).
U.S. Food and Drug Administration. Natrecor (nesiritide) for intravenous infusion, prescribing information (2009).
U.S. Food and Drug Administration. Natrecor (nesiritide) for Injection package insert (2006 revision).
O'Connor CM, et al. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure (ASCEND-HF). N Engl J Med. 2011;365:32-43.
Hernandez AF, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-40.
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
van Deursen VM, et al. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from ASCEND-HF.